We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

22 hedge funds and large institutions have $2.04M invested in Moleculin Biotech in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

22% more funds holding

Funds holding: 18 → 22 (+4)

0% less ownership

Funds ownership: 0% → 0% (-0%)

11% less capital invested

Capital invested by funds: $2.28M → $2.04M (-$241K)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
22
Holders Change
+4
Holders Change %
+22.22%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$46.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$44.4K
3
HighTower Advisors
HighTower Advisors
Illinois
+$21.3K
4
HF
HRT Financial
New York
+$8.87K
5
Squarepoint
Squarepoint
New York
+$8.87K

Top Sellers

Rank Fund Capital Flow
1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$179K
2
Wells Fargo
Wells Fargo
California
-$65.7K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$26.6K
4
UBS Group
UBS Group
Switzerland
-$21.3K
5
Barclays
Barclays
United Kingdom
-$5.32K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$756K +$46.1K +26 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$472K -$26.6K -15 -5%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$234K +$44.4K +25 +24%
Truist Financial
4
Truist Financial
North Carolina
$139K – – –
Qube Research & Technologies (QRT)
5
Qube Research & Technologies (QRT)
United Kingdom
$105K -$179K -101 -63%
WIC
6
Whitegate Investment Counselors
New Hampshire
$81K – – –
Northern Trust
7
Northern Trust
Illinois
$71K – – –
BlackRock
8
BlackRock
New York
$34K – – –
Bank of America
9
Bank of America
North Carolina
$32K – – –
UBS Group
10
UBS Group
Switzerland
$29K -$21.3K -12 -43%
HighTower Advisors
11
HighTower Advisors
Illinois
$21K +$21.3K +12 New
LWMG
12
Levy Wealth Management Group
Pennsylvania
$11K +$10.6K +6 New
Squarepoint
13
Squarepoint
New York
$10K +$8.87K +5 New
WIC
14
Woodmont Investment Counsel
Tennessee
$10K +$8.87K +5 New
HF
15
HRT Financial
New York
$8K +$8.87K +5 New
TRCT
16
Tower Research Capital (TRC)
New York
$7K +$7.1K +4 New
Barclays
17
Barclays
United Kingdom
$5K -$5.32K -3 -50%
Osaic Holdings
18
Osaic Holdings
Arizona
$4K -$5.32K -3 -60%
CAPTRUST Financial Advisors
19
CAPTRUST Financial Advisors
North Carolina
$2K – – –
APA
20
American Portfolios Advisors
New York
$1.59K – – –
Carson Wealth (CWM LLC)
21
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
GRP
22
Global Retirement Partners
California
$1K – – –
PWMG
23
Prestige Wealth Management Group
New Jersey
$1K – – –
TPWA
24
TRUE Private Wealth Advisors
Oregon
$1K – – –
CWAF
25
Core Wealth Advisors (Florida)
Florida
$1K +$1.77K +1 New
1
2

MBRX Hedge Fund Activity: Q4 2020 in Review

22 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2020, worth a combined $2.04M — down 11% from $2.28M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MBRX positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $46.1K. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $179K.

  • 22 institutional investors held Moleculin Biotech (MBRX) as of Q4 2020, up from 18 in Q3 2020.
  • Funds reported $2.04M of Moleculin Biotech stock for Q4 2020, down 11% quarter-over-quarter.
  • 7 funds opened new Moleculin Biotech positions in Q4 2020 and 2 closed out, a net change of +5 holders.
  • The largest Moleculin Biotech buyer in Q4 2020 was Renaissance Technologies, an estimated $46.1K added.
  • The largest Moleculin Biotech seller in Q4 2020 was Qube Research & Technologies (QRT), an estimated $179K sold.

Based on aggregated 13F filings for Q4 2020.